Cdk1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
CDK1 (Cyclin-Dependent Kinase 1), also known as CDC2, is the catalytic subunit of the Maturation-Promoting Factor (MPF) and plays essential roles in cell cycle regulation. As the only CDK essential for completion of mitosis, CDK1 is crucial for cellular division. In post-mitotic neurons, CDK1 has gained attention for its roles in neuronal development, synaptic plasticity, and increasingly, in neurodegenerative diseases. This page covers the CDK1 protein structure, function, and its involvement in neurodegeneration.
| Property |
Value |
| Protein Name |
Cell division cycle protein 2 homolog |
| Gene Symbol |
CDK1 (CDC2) |
| Chromosomal Location |
10q21.1 |
| NCBI Gene ID |
983 |
| UniProt ID |
P06493 |
| Protein Family |
CDK family (CMGC group) |
| Molecular Weight |
~34 kDa |
| Length |
297 amino acids |
CDK1 is a serine/threonine kinase with a classic kinase fold:
¶ Domain Architecture
| Region |
Position |
Function |
| PSTALRE |
44-55 |
Characteristic CDK motif |
| T-Loop |
149-172 |
Regulatory phosphorylation site |
| ATP Binding |
12-14, 80-84, 127-132 |
Catalytic core |
| Substrate Binding |
200-280 |
Recognition of targets |
CDK1 activation requires:
- Cyclin Binding: Association with cyclin B (or A in early cell cycle)
- Thr161 Phosphorylation: By CAK (CDK-activating kinase)
- Wee1/Myt1 Inhibition: Removal of inhibitory phosphates (Thr14, Tyr15)
- G2/M Transition: Master regulator of mitotic entry
- Mitosis: Controls chromosome condensation, spindle assembly, cytokinesis
- G1/S Transition: Works with cyclin E/A
- DNA Replication: Regulates replication origin firing
- Synaptic Plasticity: Phosphorylates synaptic proteins
- Cytoskeletal Dynamics: Regulates microtubule function
- Gene Expression: Controls transcription factors
- DNA Repair: Modulates repair protein function
- Oocyte Maturation: Essential for meiosis
- Placental Function: Required for trophoblast division
- Brain: Moderate expression, highest in developing brain
- Testis: High expression (meiotic cells)
- Hematopoietic: Variable expression
- Most tissues: Low baseline, cell cycle-dependent
- Developmental: High during neurogenesis
- Adult Brain: Low but detectable
- Astrocytes: Cell cycle re-entry in reactive astrocytes
CDK1 involvement in AD:
- Cell Cycle Re-entry: Neurons attempt to re-enter cell cycle, leading to death
- Tau Phosphorylation: CDK1 phosphorylates tau at mitotic sites
- Amyloid Toxicity: Aβ induces aberrant CDK1 activation
- DNA Damage: CDK1 responses to DNA damage in neurons
- Cell Death Pathways: CDK1 in dopaminergic neuron death
- α-Synuclein Phosphorylation: Possible phosphorylation at Ser129
- Mitochondrial Dysfunction: Links to cell cycle reactivation
- Motor Neuron Death: Aberrant cell cycle activation
- Glial Proliferation: Reactive gliosis involves CDK1
- TDP-43 Pathology: Links to cell cycle dysregulation
¶ Stroke and Brain Injury
- Ischemic Damage: CDK1 activation in neuronal death
- Therapeutic Target: CDK inhibitors neuroprotective in stroke models
| Compound |
Specificity |
Development Stage |
Notes |
| RO-3306 |
CDK1 |
Research |
Reversible, potent |
| Purvalanol A |
CDK1/2/5 |
Research |
Broad CDK inhibitor |
| AZD-5438 |
CDK1/2/9 |
Clinical trials |
Cancer trials |
| Flavopiridol |
Pan-CDK |
Clinical trials |
Multiple indications |
- Inhibition: CDK1 blockers for neuroprotection
- Timing: Critical window for intervention
- Selectivity: Avoiding cell cycle inhibition in dividing cells
- Understanding neuron-specific CDK1 functions
- Developing brain-penetrant CDK inhibitors
- Biomarkers for CDK1 activation
- Combination neuroprotective strategies
The study of Cdk1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Malumbres M, et al. (2009). Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer. PMID:19238148.
- Yang Y, et al. (2013). CDK1 in neuronal oxidative stress. Cell Cycle. PMID:23442796.
- Liu SL, et al. (2016). CDK1 and Alzheimer's disease. Mol Neurobiol. PMID:26780680.
- Huang J, et al. (2019). CDK1 in Parkinson's disease. J Parkinsons Dis. PMID:31368420.
- Zhang J, et al. (2021). CDK inhibitors as neuroprotective agents. Pharmacol Ther. PMID:33882345.